Answers are grounded in this paper and cite their sources.
// Zhaoyi Feng 1, 2, * , Wandong Xu 1, * , Chenguang Zhang 3 , Mengran Liu 1 , Hongwu Wen 1 1 Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing 100034, China 2 Center for Cancer Immunology and Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA 3 Department of Medical Genetics, Capital Medical University, Beijing 100069, China * Co-first author Correspondence to: Hongwu Wen, email: wenhongwu3184@sohu.com Keywords: epithelial ovarian carcinoma, Notch, Jagged1, NICD, γ-secretase Received: July 22, 2016 Accepted: November 07, 2016 Published: December 24, 2016 ABSTRACT Epithelial ovarian cancer (EOC) is the leading cause of death for gynecological cancer. Most patients are not diagnosed until the cancer is at an advanced stage with poor prognosis. Notch1 signaling pathway plays an oncogenic role in EOC. There have been few studies on enzymatic activity of γ-secretase and the mechanism of how γ-secretase inhibitor works on cancer cell. Here, we show that Jagged1 and NICD were highly expressed in ovarian carcinoma. The expressions of Notch1, Jagged1 and NICD in Notch1 pathway did not correlate with outcome in ovarian cancer. The enzymatic activity of γ-secretase in ovarian cancer cell lines SKOV3, CAOV3 and ES2 is significantly higher than in normal ovarian epithelial cell line T29. DAPT (a γ-secretase inhibitor) reduced the enzymatic activity of γ-secretase, inhibited the proliferation, and increased the apoptosis in ovarian cancer cell lines. Hence, γ-secretase inhibitor may become a highly promising novel therapeutic strategy against ovarian cancer in the field of precision medicine.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: